The in vivo tests showed that the nanoparticle-based formulations loading hydrocortisone were efficient in reducing the severity of the pathological features of AD, including the production and release of IgE, histamine, prostaglandin-E2, vascular endothelial growth factor-α (VEGF-α), and others AD-associated inflammatory mediators [101]. Here, VEGFA is linked to Alzheimer disease.